Exosome Diagnostics, Inc.

Exosome Diagnostics, Inc. specializes in innovative diagnostic solutions for prostate cancer, offering advanced liquid biopsy tests that aid in non-invasive patient assessments and clinical decision-making. Founded in 2008 and headquartered in Waltham, US, Exosome Diagnostics, Inc. develops diagnostic solutions focused on prostate cancer detection.

The company received funding through a Series C round on July 5, 2017, securing USD 30. 29 mn from investors including Tiger Advisors and Forbion Capital Partners. CEO Shelly Hirshon leads the firm, which has completed 7 deals to date. Exosome Diagnostics, Inc.

specializes in advanced diagnostic solutions for prostate cancer, primarily through its flagship product, the ExoDx Prostate Test. This exosome-based liquid biopsy test is designed to provide a non-invasive method for assessing prostate cancer risk, specifically targeting patients with Prostate-Specific Antigen (PSA) levels in the 'gray zone' of 2–10 ng/mL. The test assists in guiding biopsy decisions by distinguishing between high-grade and low-grade prostate cancer as well as benign conditions, facilitating earlier disease detection. The ExoDx Prostate Test is recognized in clinical guidelines from the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA), reinforcing its clinical relevance.

Exosome Diagnostics serves a diverse range of clients, including healthcare providers, urologists, and institutions, primarily within the United States. The company has also expanded access to veterans, who are at an increased risk for prostate cancer, further broadening its market reach. Exosome Diagnostics operates on a revenue model centered around its proprietary ExoDx Prostate Test and related services. The company engages in business-to-business transactions with healthcare providers and institutions, directly offering its tests to clinicians who utilize them in patient evaluations.

Revenue is generated through the sale of the ExoDx Prostate Test, which involves a straightforward transaction structure where healthcare providers order the test for their patients. The firm provides an at-home collection kit to facilitate sample collection, enhancing accessibility for patients and increasing test uptake. Specific pricing structures for the ExoDx Prostate Test are established based on the delivery of clinical services, emphasizing the test's utility in clinical decision-making for prostate cancer management. Exosome Diagnostics, Inc.

aims to expand its product offerings and market presence following its Series C funding of USD 30. 29 mn secured on July 5, 2017. The company plans to develop new diagnostic tests targeted at additional cancer types and enhance its existing pipeline. Furthermore, Exosome Diagnostics is exploring expansion into international markets, with a focus on Europe and Asia by 2025.

The recent funding will support the development of these new products, as well as marketing efforts to increase accessibility and awareness of its tests.